

UNITED STATES BANKRUPTCY COURT

Northern DISTRICT OF Texas

Dallas Division

In re: EIGER BIOPHARMACEUTICALS, INC., et al.

§
§
§
§

Debtor(s)

Case No. 24-80040

Lead Case No. 24 - 80040

☒ Jointly Administered**Post-confirmation Report**

Chapter 11

Quarter Ending Date: 03/31/2026

Petition Date: 04/01/2024

Plan Confirmed Date: 09/05/2024

Plan Effective Date: 09/30/2024

This Post-confirmation Report relates to: ☐ Reorganized Debtor☒ Other Authorized Party or Entity: Liquidating Trust for Eiger BioPharmaceuticalName of Authorized Party or
Entity

/s/ Margie Venus

Signature of Responsible Party

05/12/2026

Date

Margie Venus

Printed Name of Responsible Party

600 Travis Street, Suite 7000
Houston, Texas, 77002

Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al.

Case No. 24-80040

Part 1: Summary of Post-confirmation Transfers

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	\$278,441	\$13,562,505
b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$278,441	\$13,562,505

Part 2: Preconfirmation Professional Fees and Expenses

a.			Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative	
	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor <i>Aggregate Total</i>		\$0	\$14,404,360	\$0	\$14,404,360	
	<i>Itemized Breakdown by Firm</i>						
		Firm Name	Role				
	i	Alvarez & Marsal	Financial Professional	\$0	\$3,452,114	\$0	\$3,452,114
	ii	KCC, LCC	Other	\$0	\$953,110	\$0	\$953,110
	iii	Sidley Austin LLP	Lead Counsel	\$0	\$8,331,110	\$0	\$8,331,110
	iv	SSG Advisors, LLC	Other	\$0	\$155,031	\$0	\$155,031
	v	Porzio, Bromberg & Newm	Co-Counsel	\$0	\$978,267	\$0	\$978,267
	vi	McKool Smith PC	Co-Counsel	\$0	\$452,130	\$0	\$452,130
	vii	Dundon Advisers LLC	Financial Professional	\$0	\$82,598	\$0	\$82,598
	viii						
	ix						
	x						
	xi						
	xii						
	xiii						
	xiv						
	xv						
	xvi						
	xvii						
	xviii						
	xix						
	xx						
	xxi						
	xxii						
	xxiii						
	xxiv						
	xxv						
xxvi							
xxvii							
xxviii							
xxix							

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al.

Case No. 24-80040

xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al.

Case No. 24-80040

lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvii						
lxxxviii						
lxxxix						
xc						
xc i						
xc ii						
xc iii						
xc iv						
xc v						
xc vi						
xc vii						
xc viii						
xc ix						
c						
ci						

b.			Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor					
	<i>Aggregate Total</i>					
	<i>Itemized Breakdown by Firm</i>					
	Firm Name	Role				
	i					
	ii					
	iii					
	iv					
	v					
	vi					

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al.

Case No. 24-80040

vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al.

Case No. 24-80040

xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvii						
lxxxviii						
lxxxix						
xc						

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al.

Case No. 24-80040

	xc						
	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						
c.	All professional fees and expenses (debtor & committees)						

Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	\$0	\$0	\$0	\$0	0%
b. Secured claims	\$0	\$0	\$0	\$0	0%
c. Priority claims	\$276,440	\$0	\$197,372	\$276,440	71%
d. General unsecured claims	\$3,760,715	\$0	\$3,288,195	\$3,760,715	87%
e. Equity interests	\$6,736,437	\$0	\$5,750,000		

Part 4: Questionnairea. Is this a final report? Yes ☐ No ☒

If yes, give date Final Decree was entered: _____

If no, give date when the application for Final Decree is anticipated: _____

b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ☒ No ☐

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.

/s/ Joshua Nahas

Signature of Responsible Party

Liquidating Trustee


Title

Joshua Nahas


Printed Name of Responsible Party

05/12/2026


Date




Page 1




Other Page 1




Page 2 Minus Tables




Bankruptcy Table 1-50




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-50



Non-Bankruptcy Table 51-100



Part 3, Part 4, Last Page